AF
URGN icon

Amalgamated Financial’s UroGen Pharma URGN Stock Holding History

Amalgamated Financial’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$26K Buy
+2,960
New +$23.1K ﹤0.01% 2668

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Amalgamated Financial's URGN Position: Q1 2022 in Review

Amalgamated Financial opened a new position in UroGen Pharma (URGN) in Q1 2022: 2,960 shares worth $26K. The stake represents ﹤0.01% of the portfolio and ranks #2668 among its holdings.

84 funds tracked by Wall St. Rank hold URGN as of Q1 2022.

  • Amalgamated Financial held 2,960 shares of UroGen Pharma worth $26K as of Q1 2022.
  • UroGen Pharma was a new Amalgamated Financial position in Q1 2022.
  • UroGen Pharma made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2668 holding.
  • 84 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.